Case studies in current drug development: ‘glycylcyclines’

2006 ◽  
Vol 10 (4) ◽  
pp. 374-379 ◽  
Author(s):  
Phaik-Eng Sum
Keyword(s):  
Drug Development ◽  
Case Studies ◽  
Current Drug

scholarly journals Towards Academic Drug Development Guidelines

2019 ◽  
Author(s):  
Christopher Southan
Keyword(s):  
Drug Development ◽  
Success Rate ◽  
Case Studies ◽  
Small Molecule ◽  
Research Productivity ◽  
Medicinal Chemistry ◽  
Academic Development ◽  
Commercial Development ◽  
Small Molecule Drug

This report covers academic small-molecule drug development with a view to distilling guidelines. The first section covers research productivity feeding into commercial development before reviewing the literature on statistics of academic development It then considers differences between probes and drugs before discussing the role of author guidelines in medicinal chemistry and pharmacology journals. Resources for comprehensive compound and target cross-checking are then covered followed by comparisons between public and commercial databases including case studies of selected compounds. It concludes with an outline of new scientific developments that could increase the success rate of academic drug development.

scholarly journals Towards Academic Drug Development Guidelines

2019 ◽  
Author(s):  
Christopher Southan
Keyword(s):  
Drug Development ◽  
Success Rate ◽  
Case Studies ◽  
Small Molecule ◽  
Research Productivity ◽  
Medicinal Chemistry ◽  
Academic Development ◽  
Commercial Development ◽  
Small Molecule Drug

This report covers academic small-molecule drug development with a view to distilling guidelines. The first section covers research productivity feeding into commercial development before reviewing the literature on statistics of academic development It then considers differences between probes and drugs before discussing the role of author guidelines in medicinal chemistry and pharmacology journals. Resources for comprehensive compound and target cross-checking are then covered followed by comparisons between public and commercial databases including case studies of selected compounds. It concludes with an outline of new scientific developments that could increase the success rate of academic drug development.

Weaknesses in the System of Promoting and Marketing Drugs

1974 ◽  
Vol 4 (3) ◽  
pp. 260-263
Author(s):  
James Turner
Keyword(s):  
Public Sector ◽  
Pharmaceutical Industry ◽  
Drug Development ◽  
Economic Structure ◽  
Drug Industry ◽  
Specific Drug ◽  
The Public ◽  
Current Drug ◽  
Consumer Organizations ◽  
The Impact

Although critical of several specific drug industry practices as being major contributions to the current over-medicated society controversy, Mr. Turner believes that the pharmaceutical industry can work together with consumer organizations and the public sector in resolving these issues. Of particular interest is his observation that the economic structure of current drug development and research prevents the manufacturer from assessing the impact of a drug in terms of necessary health benefits.

Current drug development portfolio for antimalarial therapies

2005 ◽  
Vol 5 (5) ◽  
pp. 473-478 ◽  
Author(s):  
G BIAGINI ◽  
P ONEILL ◽  
P BRAY ◽  
S WARD
Keyword(s):  
Drug Development ◽  
Current Drug
Sign in / Sign up

Export Citation Format

Share Document